on constatait que : -94,4% des patients avaient au moins un effet indésirable. Seuls deux patients ont été indemnes d'effets indésirables ,
l'incidence d'une anémie se majorait de 20% (50% pour le bocéprévir et 40% pour le télaprévir), ainsi que la sévérité (49). Cependant, dans notre cohorte, le taux d'anémie était de 30% avec un taux moyen similaire de 10 ,
The global health burden of hepatitis C virus infection, Liver International, vol.31, issue.(Suppl. 2), 2011. ,
DOI : 10.1111/j.1478-3231.2011.02537.x
Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C, Annals of Internal Medicine, vol.149, issue.6, pp.399-403, 2008. ,
DOI : 10.7326/0003-4819-149-6-200809160-00006
Future treatment of patients with HCV cirrhosis, Liver International, vol.54, issue.suppl, pp.113-119, 2012. ,
DOI : 10.1111/j.1478-3231.2011.02702.x
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis, Gut, vol.61, issue.2, pp.290-296, 2012. ,
DOI : 10.1136/gutjnl-2011-300586
Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ???true life???, European Journal of Gastroenterology & Hepatology, vol.22, issue.11, pp.1297-1302, 2010. ,
DOI : 10.1097/MEG.0b013e32833bb4b0
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) ??? NCT01514890, Journal of Hepatology, vol.59, issue.3, pp.434-475, 2013. ,
DOI : 10.1016/j.jhep.2013.04.035
Épidémiologie de l'infection par le virus de l'hépatite C en France, Hépato-Gastro, vol.19, issue.8, pp.635-640, 2012. ,
Du virus à l'histoire naturelle de l'hépatite C. Hépato-Gastro, pp.641-648, 2012. ,
Hépatite C chronique: apport des antiprotéases, télaprévir et bocéprévir, Dossier du CNHIM, vol.1, pp.7-66, 2013. ,
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver, Liver International, vol.56, issue.17, pp.1477-1492, 2012. ,
DOI : 10.1111/j.1478-3231.2012.02856.x
A new challenge for the HCV research, Virologie, vol.10, pp.159-165, 2006. ,
Replication of hepatitis C virus, Nature Reviews Microbiology, vol.281, issue.6, pp.453-463, 2007. ,
DOI : 10.1038/nrmicro1645
URL : https://hal.archives-ouvertes.fr/hal-00313684
Hépatite C : un pas vers l'éradication ? [en ligne] ,
Les nouvelles molécules à l'EASL [en ligne], 2013. ,
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C, New England Journal of Medicine, vol.368, issue.1, pp.34-44, 2013. ,
DOI : 10.1056/NEJMoa1208953
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.381, issue.9883, pp.2100-2107, 2013. ,
DOI : 10.1016/S0140-6736(13)60247-0
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-1887, 2013. ,
DOI : 10.1056/NEJMoa1214853
GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial, J Hepatol, vol.58, pp.663-668, 2013. ,
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options, New England Journal of Medicine, vol.368, issue.20, pp.1867-1877, 2013. ,
DOI : 10.1056/NEJMoa1214854
Faldaprevir and Deleobuvir for HCV Genotype 1 Infection, New England Journal of Medicine, vol.369, issue.7, pp.630-639, 2013. ,
DOI : 10.1056/NEJMoa1213557
1 en échec de trithérapie par télaprévir ou bocéprévir avec une association orale par daclatasvir, sofosbuvir avec ou sans ribavirine [en ligne100-de-reponse-virologique- soutenue-chez-des-patients-g-1-en-echec-de-tritherapie-par-telaprevir-ou-boceprevir-avec-une- association-orale-par-daclatasvir-sofosbuvir-avec-ou-sans-ribavirine, 1499. ,
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial, Gastroenterology, vol.137, issue.6, 1986. ,
DOI : 10.1053/j.gastro.2009.08.067
Liver stiffness diminishes with antiviral response in chronic hepatitis C, Alimentary Pharmacology & Therapeutics, vol.42, issue.6, pp.656-663, 2011. ,
DOI : 10.1111/j.1365-2036.2011.04765.x
Traitement de l'hépatite C. [en ligne], 2002. ,
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-593, 2009. ,
DOI : 10.1056/NEJMoa0808010
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy, Gastroenterology, vol.136, issue.5, pp.1618-1628, 2009. ,
DOI : 10.1053/j.gastro.2009.01.039
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-1850, 2009. ,
DOI : 10.1056/NEJMoa0807650
Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-1303, 2010. ,
DOI : 10.1056/NEJMoa0908014
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.376, issue.9742, pp.705-716, 2010. ,
DOI : 10.1016/S0140-6736(10)60934-8
Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011. ,
DOI : 10.1056/NEJMoa1010494
URL : https://hal.archives-ouvertes.fr/hal-00867494
Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2428, 2011. ,
DOI : 10.1056/NEJMoa1013086
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection, New England Journal of Medicine, vol.365, issue.11, pp.1014-1024, 2011. ,
DOI : 10.1056/NEJMoa1014463
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1217, 2011. ,
DOI : 10.1056/NEJMoa1009482
Organisation du traitement antiviral C et effets secondaires, Hépato-Gastro, vol.19, pp.661-667, 2012. ,
Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis, Current Opinion in Internal Medicine, vol.7, issue.2, pp.23-28, 2008. ,
DOI : 10.1097/BOR.0b013e3282f1330c
URL : https://hal.archives-ouvertes.fr/hal-00684157
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus, Gastroenterology, vol.139, issue.1, pp.120-129, 2010. ,
DOI : 10.1053/j.gastro.2010.04.013
Traitement de l'hépatite chronique virale C : infection par un génotype non 1, Hépato- Gastro, vol.19, pp.683-686, 2012. ,
Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?, Journal of Hepatology, vol.58, issue.2, pp.391-394, 2013. ,
DOI : 10.1016/j.jhep.2012.09.023
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin, Hepatology, vol.14, issue.4, pp.1122-1126, 2010. ,
DOI : 10.1002/hep.23444
Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice, World Journal of Gastroenterology, vol.18, issue.12, pp.1339-1347, 2012. ,
DOI : 10.3748/wjg.v18.i12.1339
A Small Percentage of Patients With Hepatitis C Receive Triple Therapy With Boceprevir or Telaprevir, Clinical Gastroenterology and Hepatology, vol.11, issue.8, pp.1014-1020, 2013. ,
DOI : 10.1016/j.cgh.2013.03.032
Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?, Journal of Viral Hepatitis, vol.364, issue.Suppl. 4, pp.677-684, 2012. ,
DOI : 10.1111/jvh.12003
IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?, Liver International, vol.54, issue.Suppl. 1, pp.74-78, 2012. ,
DOI : 10.1111/j.1478-3231.2011.02712.x
Pegylated interferon-??2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003???2007), Antiviral Therapy, vol.17, issue.1, pp.101-110, 2003. ,
DOI : 10.3851/IMP1935
The changing relative prevalence of hepatitis C virus genotypes: Evidence in hemodialyzed patients and kidney recipients, Gastroenterology, vol.108, issue.2, pp.581-583, 1995. ,
DOI : 10.1016/0016-5085(95)90088-8
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice, Liver International, vol.31, issue.Suppl. 1, pp.32-38, 2012. ,
DOI : 10.1111/j.1478-3231.2011.02707.x
efficacité et tolérance 12 semaines après l'arrêt de la trithérapie. [en ligne]cupic-efficacite-et-tolerance-12-semaines- apres-l-arret-de-la-tritherapie, 1461. ,
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-965, 2001. ,
DOI : 10.1016/S0140-6736(01)06102-5
SVR 12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC) ,
Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial, Gastroenterology, pp.16-5085, 2013. ,